Added value of [F]FDOPA PET to the management of high-grade glioma patients after their initial treatment: a prospective multicentre study.
Fiche publication
Date publication
avril 2023
Journal
European journal of nuclear medicine and molecular imaging
Auteurs
Membres identifiés du Cancéropôle Est :
Pr TAILLANDIER Luc, Pr VERGER Antoine
Tous les auteurs :
Darcourt J, Chardin D, Bourg V, Gal J, Schiappa R, Blonski M, Koulibaly PM, Almairac F, Mondot L, Le Jeune F, Collombier L, Kas A, Taillandier L, Verger A
Lien Pubmed
Résumé
Diagnostic value of 3,4-dihydroxy-6-[F]fluoro-L-phenylalanine ([F]FDOPA) PET in patients with suspected recurrent gliomas is recognised. We conducted a multicentre prospective study to assess its added value in the practical management of patients suspected of recurrence of high grade gliomas (HGG).
Mots clés
Diagnostic efficacy, Glioblastoma recurrence, High-grade gliomas recurrence, Patients’ management, [18F]FDOPA PET
Référence
Eur J Nucl Med Mol Imaging. 2023 04 22;: